Paratek Pharmaceuticals Stock Forecast, Price & News

-0.29 (-2.71 %)
(As of 06/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume441,662 shs
Average Volume460,694 shs
Market Capitalization$489.46 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Paratek Pharmaceuticals logo

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.39 out of 5 stars

Medical Sector

745th out of 2,100 stocks

Pharmaceutical Preparations Industry

371st out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

Is Paratek Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Paratek Pharmaceuticals stock.
View analyst ratings for Paratek Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Paratek Pharmaceuticals?

Wall Street analysts have given Paratek Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Paratek Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Paratek Pharmaceuticals

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its quarterly earnings results on Monday, May, 17th. The specialty pharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.17. The specialty pharmaceutical company had revenue of $16.43 million for the quarter, compared to analyst estimates of $32.83 million.
View Paratek Pharmaceuticals' earnings history

How has Paratek Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PRTK stock has increased by 168.1% and is now trading at $10.43.
View which stocks have been most impacted by COVID-19

What price target have analysts set for PRTK?

4 Wall Street analysts have issued twelve-month price objectives for Paratek Pharmaceuticals' stock. Their forecasts range from $10.00 to $22.00. On average, they expect Paratek Pharmaceuticals' share price to reach $15.25 in the next year. This suggests a possible upside of 46.2% from the stock's current price.
View analysts' price targets for Paratek Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the following people:
  • Mr. Michael F. Bigham CPA, M.B.A., CPA, MBA, Exec. Chairman (Age 63, Pay $899.7k)
  • Dr. Evan Loh, CEO & Director (Age 62, Pay $1.03M)
  • Mr. Adam Woodrow, Pres & Chief Commercial Officer (Age 54, Pay $711.87k)
  • Ms. Sarah Higgins, VP, Controller and Interim Principal Financial & Accounting Officer (Age 46)
  • Mr. Jason Burdette, Sr. VP of Technical Operations
  • Mr. Ben Strain, VP of Investor Relations & Corp. Communications and Chief of Staff to the CEO
  • Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 59)
  • Ms. Karen McGrath, Sr. VP of HR
  • Mr. Randall B. Brenner, Chief Devel. & Regulatory Officer (Age 48)

Who are some of Paratek Pharmaceuticals' key competitors?

What other stocks do shareholders of Paratek Pharmaceuticals own?

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.41%), Rock Springs Capital Management LP (3.59%), General American Investors Co. Inc. (2.10%), Geode Capital Management LLC (1.48%), Renaissance Technologies LLC (1.29%) and Northern Trust Corp (1.04%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner and William M Haskel.
View institutional ownership trends for Paratek Pharmaceuticals

Which institutional investors are selling Paratek Pharmaceuticals stock?

PRTK stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Renaissance Technologies LLC, Weil Company Inc., Northern Trust Corp, Stifel Financial Corp, Essex Investment Management Co. LLC, Los Angeles Capital Management LLC, and General American Investors Co. Inc.. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner, and William M Haskel.
View insider buying and selling activity for Paratek Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Paratek Pharmaceuticals stock?

PRTK stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, CM Management LLC, Perkins Capital Management Inc., Geode Capital Management LLC, New York State Common Retirement Fund, BlackRock Inc., Barclays PLC, and XTX Topco Ltd.
View insider buying and selling activity for Paratek Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $10.43.

How much money does Paratek Pharmaceuticals make?

Paratek Pharmaceuticals has a market capitalization of $489.46 million and generates $46.92 million in revenue each year. The specialty pharmaceutical company earns $-96,540,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis.

How many employees does Paratek Pharmaceuticals have?

Paratek Pharmaceuticals employs 196 workers across the globe.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is

Where are Paratek Pharmaceuticals' headquarters?

Paratek Pharmaceuticals is headquartered at 75 PARK PLAZA, BOSTON MA, 02116.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.